Project Details
Description
A randomized, blinded, phase 2 dose-ranging study of BMS-936558 in subjects with progressive advanced/metastatic clear cell renal carcinoma who have received prior anti-angiogenic therapy
| Status | Finished |
|---|---|
| Effective start/end date | 3/21/11 → 8/31/15 |
Funding
- BRISTOL-MYERS SQUIBB PHARM RES
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.